Kurita America v. IFF: Bioprocessing Enzyme Patent Case Settles in 134 Days
Kurita America, Inc. filed suit against International Flavors & Fragrances in the Western District of Wisconsin, asserting three patents covering enzyme-based fermentation and bioprocessing technology tied to IFF products including Distillase® SSF+, Optimash® Phytase, and the XCELIS® platform. The case resolved by settlement in just 134 days — before the preliminary pretrial conference was even held.
Enzyme IP clash between water treatment and flavors giants ends quietly
On December 19, 2024, Kurita America, Inc. filed a patent infringement complaint against International Flavors & Fragrances (IFF) in the U.S. District Court for the Western District of Wisconsin. Kurita asserted three patents — US8415137B2, US10954535B2, and US8609399B2 — covering bioprocessing enzyme technologies. The accused IFF products included Distillase® SSF+, Optimash® Phytase, Spezyme® RSL, the XCELIS® platform, and pHytOUT® Technology, all of which are commercially deployed enzyme solutions for fermentation and agricultural bioprocessing applications.
The case closed on May 2, 2025, when the parties jointly notified the court of a settlement and requested deferrals on deadlines. District Judge James D. Peterson declined to simply pause proceedings and instead dismissed the case without prejudice, with leave for either party to move to reopen on good cause shown. The order also noted that parties may later seek dismissal with prejudice once the settlement is fully executed — a standard procedural posture for settlement-driven closures at this stage.
The 134-day resolution is notably rapid for multi-patent infringement litigation of this commercial complexity, suggesting either pre-existing licensing discussions or significant early leverage — potentially tied to the breadth of IFF’s accused product portfolio. The terms of the settlement remain confidential, and the without-prejudice dismissal means the litigation record does not reflect any admission of infringement or validity finding. What drove the specific resolution — royalties, cross-licensing, or exit payments — is not discernible from the public docket.
Filing to Case Settled in 134 days
134 days — faster than typical district court patent resolution, suggesting early settlement pressure
Case dismissed without prejudice: what the settlement posture means for both parties
Without-prejudice dismissal preserves future options
Judge Peterson dismissed the case without prejudice rather than granting a simple deadline deferral. This means the litigation record is wiped clean — no merits ruling, no invalidity finding, no infringement determination. Kurita retains the right to refile on the same patents if the settlement breaks down, provided good cause is shown to reopen. Parties may later convert to a with-prejudice dismissal once the settlement agreement is fully executed.
Rule 41 / without prejudiceKurita’s patents survive unscathed — enforceability intact
Because the dismissal is without prejudice and no court ruled on validity or infringement, all three Kurita patents — US8415137B2, US10954535B2, and US8609399B2 — remain fully enforceable. There is no estoppel or narrowing of claim scope arising from this proceeding. Kurita can assert these patents against other parties, including any future infringers in the enzyme and fermentation sector, without any adverse litigation history attached.
Patents remain enforceableIFF exits without an invalidity ruling — but settlement terms bind conduct
IFF avoids any public finding of infringement, which protects its commercial reputation and product lines including Distillase® SSF+, Optimash® Phytase, and the XCELIS® platform. However, settlement agreements in patent cases typically include licensing terms, product restrictions, or royalty obligations that are not reflected in the public record. IFF’s litigation posture — retaining Finnegan Henderson alongside DeWitt LLP — signals it prepared a substantive defense, consistent with a negotiated rather than capitulated exit.
No infringement findingEnzyme bioprocessing IP remains a live enforcement area
This case confirms that enzyme technology patents covering fermentation optimization, phytase applications, and starch liquefaction remain commercially valuable and actively enforced. Competitors developing or marketing products in overlapping categories — particularly in fuel ethanol, food enzyme, and agricultural bioprocessing — should treat these three Kurita patents as active risk assets. The rapid settlement, before claim construction or discovery, suggests both parties saw value in avoiding public scrutiny of the patent scope and product design.
Active IP enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Kurita America, Inc. | Company | Water treatment and bioprocessing solutions firm — holder of US8415137B2, US10954535B2, US8609399B2Search in Eureka ↗ |
| Defendant | International Flavors & Fragrances | Individual | Global flavors, fragrances, and bioprocessing ingredient company; maker of accused enzyme productsSearch in Eureka ↗ |
| Plaintiff counsel | Aaron E. Schindler | Attorney | Counsel for Kurita America, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Autumn Nero | Attorney | Counsel for Kurita America, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brandon Michael Lewis | Attorney | Counsel for Kurita America, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher G. Hanewicz | Attorney | Counsel for Kurita America, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michelle M. Kemp | Attorney | Counsel for Kurita America, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Perkins Coie LLP | Law Firm | Representing Kurita America, Inc.Search in Eureka ↗ |
| Defendant counsel | Brandon Thomas Andersen | Attorney | Counsel for International Flavors & FragrancesSearch in Eureka ↗ |
| Defendant counsel | Jeanette Roorda | Attorney | Counsel for International Flavors & FragrancesSearch in Eureka ↗ |
| Defendant counsel | Laura Marie Davis | Attorney | Counsel for International Flavors & FragrancesSearch in Eureka ↗ |
| Defendant counsel | Michael J. Flibbert | Attorney | Counsel for International Flavors & FragrancesSearch in Eureka ↗ |
| Defendant counsel | Pier DeRoo | Attorney | Counsel for International Flavors & FragrancesSearch in Eureka ↗ |
| Defendant law firm | DeWitt LLP | Law Firm | Representing International Flavors & FragrancesSearch in Eureka ↗ |
| Defendant law firm | Finnegan, Henderson, Farabow, Garrett & Dunner LLP | Law Firm | Representing International Flavors & FragrancesSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Wisconsin Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
Judge Peterson’s order reflects a pragmatic judicial approach: rather than freezing proceedings at the parties’ request, the court imposed a clean without-prejudice dismissal. The phrasing — ‘any party may move to reopen the case on a showing of good cause’ — preserves judicial oversight of any settlement breakdown while relieving docket burden. The express invitation to convert to a with-prejudice dismissal post-execution is standard and signals the court anticipates the settlement will complete. Critically, no merits ruling was made on infringement or validity of the three asserted patents.
US8415137B2, US10954535B2 & US8609399B2 — Bioprocessing Enzyme Technology
US8415137B2 (App. No. 13/274075), US10954535B2 (App. No. 16/178107), and US8609399B2 (App. No. 13/489067) collectively cover enzyme-based technologies deployed in industrial fermentation and bioprocessing. These patents address methods and compositions relating to simultaneous saccharification and fermentation, phytase activity optimization, and starch-processing enzyme systems. The application genealogy — spanning two generations of application numbers — suggests a sustained R&D investment by Kurita in this technical domain, with later patents likely refining or extending earlier enzymatic approaches.
In the industrial enzyme sector, patents covering fermentation optimization and phytase activity are strategically significant because they underpin high-volume applications in fuel ethanol production, animal nutrition, and food ingredient manufacturing. IFF’s accused products — including the XCELIS® platform and pHytOUT® Technology — are positioned as premium enzyme solutions for exactly these markets. For competitors active in grain processing, distillery enzymes, or feed additive formulation, these three patents represent a meaningful freedom-to-operate risk that survived this litigation without any claim narrowing or invalidation.
Should you run an FTO against US8415137B2, US10954535B2, and US8609399B2?
Any R&D or product team developing enzyme formulations for fermentation, phytase applications, starch liquefaction, or simultaneous saccharification processes should treat these three Kurita patents as live risk assets. The case against IFF — covering five commercial enzyme products — demonstrates that Kurita is willing to assert broadly across an enzyme portfolio. The without-prejudice dismissal means no claim scope limitation arises from this litigation, leaving the patents at their full issued breadth.
PatSnap Eureka’s FTO Search Agent enables targeted freedom-to-operate analysis against US8415137B2, US10954535B2, and US8609399B2. Users can map specific enzyme formulation claims against their own product workflows, identify design-around opportunities, and monitor Kurita’s broader patent portfolio for continuation filings that may extend coverage into adjacent bioprocessing applications. Proactive FTO analysis now avoids the settlement pressure IFF faced.
Run a freedom-to-operate analysis on US8415137B2 to assess your product’s exposure
Run FTO in Eureka →Similar enzyme and bioprocessing patent cases in U.S. district courts
Explore related patent infringement actions involving industrial enzyme, fermentation, and bioprocessing technology litigated in U.S. district courts.
What this case signals for the bioprocessing enzyme IP landscape
A swift pre-discovery settlement between two major players highlights how enzyme technology patents are reshaping competitive dynamics in industrial bioprocessing.
Pre-discovery settlement signals strong plaintiff leverage in enzyme IP
Kurita’s three patents cover core fermentation enzyme processes tied to commercially deployed IFF products. The fact that IFF — a well-resourced defendant with top-tier patent counsel — settled before claim construction suggests the asserted claims presented credible infringement risk. Enzyme technology patent holders should note the speed: asserting broad bioprocessing claims early can force rapid licensing conversations.
IFF’s multi-product exposure amplified settlement pressure
Five IFF products were named as accused: Distillase® SSF+, Optimash® Phytase, Spezyme® RSL, XCELIS® platform, and pHytOUT® Technology. Multi-product exposure across a commercial enzyme portfolio typically elevates damages exposure and strengthens plaintiff’s hand. Companies with broad enzyme portfolios should proactively audit patent risk across their full product lines, not just flagship SKUs.
Kurita v International — key questions answered
Kurita America asserted three patents: US8415137B2, US10954535B2, and US8609399B2. These cover enzyme technologies for bioprocessing, including simultaneous saccharification and fermentation, phytase activity, and starch-processing enzyme compositions. The accused IFF products included Distillase® SSF+, Optimash® Phytase, Spezyme® RSL, the XCELIS® platform, and pHytOUT® Technology.
The case settled. On May 2, 2025, District Judge James D. Peterson dismissed the case without prejudice after the parties filed a notice of settlement. The court declined to simply defer deadlines and instead issued the dismissal, with leave for parties to later seek a with-prejudice dismissal upon full execution of the settlement agreement. Settlement terms are confidential.
A without-prejudice dismissal means the case ended without any merits ruling. Kurita’s three patents — US8415137B2, US10954535B2, and US8609399B2 — remain fully enforceable with no court-imposed narrowing of claim scope. Kurita retains the right to assert these patents against other parties or, if good cause arises, to move to reopen this specific case against IFF.
The 134-day resolution, before any pretrial conference or claim construction, suggests either pre-existing licensing negotiations between the parties or early recognition of significant infringement risk by IFF. The breadth of accused products — five commercial enzyme solutions — likely amplified damages exposure and strengthened Kurita’s negotiating position. The specific settlement terms, including any royalty or licensing arrangements, are not disclosed in the public record.
The settlement terms are confidential, so it is not possible to confirm from public records whether IFF obtained a license, agreed to design-arounds, or accepted other restrictions. The without-prejudice dismissal means no infringement was adjudicated. If the parties execute a full settlement and later file a with-prejudice dismissal, that would signal a more permanent resolution — but the product risk profile for third parties developing similar enzyme technologies remains unchanged, as the Kurita patents are unimpaired.
PatSnap Eureka searches patents and litigation data to answer instantly.